Candel Therapeutics (CADL) Cash from Operations: 2020-2024
Historic Cash from Operations for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$27.0 million.
- Candel Therapeutics' Cash from Operations fell 7.80% to -$7.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.2 million, marking a year-over-year decrease of 8.99%. This contributed to the annual value of -$27.0 million for FY2024, which is 21.09% up from last year.
- Candel Therapeutics' Cash from Operations amounted to -$27.0 million in FY2024, which was up 21.09% from -$34.2 million recorded in FY2023.
- In the past 5 years, Candel Therapeutics' Cash from Operations ranged from a high of -$9.1 million in FY2020 and a low of -$34.2 million during FY2023.
- Moreover, its 3-year median value for Cash from Operations was -$31.4 million (2022), whereas its average is -$30.9 million.
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 144.93% in 2021, then rose by 21.09% in 2024.
- Candel Therapeutics' Cash from Operations (Yearly) stood at -$9.1 million in 2020, then crashed by 144.93% to -$22.2 million in 2021, then crashed by 41.41% to -$31.4 million in 2022, then decreased by 8.99% to -$34.2 million in 2023, then increased by 21.09% to -$27.0 million in 2024.